--- title: "Dow 30 Earnings: Merck First Quarter Fiscal 2017" description: dow 30 earnings, Merck & Co. stock solid core holding investors seeking participation large pharmaceutical space, adjusted earnings outlook $3.76-$3.88 a share image: https://investor.valueline.com/hubfs/VL%20Blog%20Images/iStock-506712124.jpg --- [![The Value Line Blog](https://investor.valueline.com/hubfs/VL%20Blog%20Images/vl_blog_header.png)](https://investor.valueline.com/blog) [Stock Highlights](https://investor.valueline.com/blog/topic/stock-highlights) # Dow 30 Earnings: Merck First Quarter Fiscal 2017 May 2, 2017 New Jersey-based drugmaker and Dow-30 component **Merck** ([MRK](https://research.valueline.com/research#sec=company&sym=MRK)- [Free Merck Stock Report](https://research.valueline.com/api/report?documentID=2185-VL_20170407_VLIS_MRK_2009_01-5DN38BS4EGJCLTDSGOSKDVT5NO&symbol=MRK)) has reported first-quarter earnings of $0.56 a share, versus $0.40 in the comparable period of 2016. The bottom-line improvement was driven by continued reductions in production costs (-16%) and modestly higher revenues (+1%). Meantime, adjusted earnings, which exclude one-time gains, charges, and other nonrecurring items, and are more closely followed by Wall Street, came in at $0.88 a share, versus $0.89 in 2015. While it represented the second-consecutive quarter of decline, the adjusted figure topped consensus expectations by roughly a nickel, thanks to higher gross margins and better-than-anticipated growth in revenues. The revenues gain was due to strength in the oncology, vaccine, and animal health franchises. Given the solid quarter, management raised its 2017 adjusted earnings outlook to $3.76-$3.88 a share (previously $3.72-$3.87). Shares of MRK are trading relatively flat on the release. In the March period, worldwide revenues advanced 1% year over year, to $9.43 billion. The gain was highlighted by continued momentum in Merck's standout oncology asset *KEYTRUDA* (sales +137%) and a strong seasonal bump in vaccine franchise *GARDASIL* (+41%). A solid performance from new Hep-C drug *ZEPATIER* and a double-digit increase in animal health sales (+13%) further bolstered results, helping to offset generic pressures on several off-patent drugs, including *ZETIA/VYTORIN* (-35%), *REMICADE* (-34%), *CUBICIN* (-67%), and *NASONEX* (-40%). Softness in the company's top-grossing *JANUVIA/JANUMET* diabetes franchise was also a drag (sales -5%), due to the timing of purchases in the United States. For full-year 2017, management is guiding for revenues of $39.1 billion to $40.3 billion, which includes a 1.5% negative impact from foreign exchange at mid-April rates. With Merck facing a significant patent cliff in 2017, continued momentum in the new product cycle and a keen focus on cost controls will be key to offsetting generic erosion. The company's top asset and now second-highest-grossing franchise, *KEYTRUDA*, will be leaned on heavily. The drug added a few more regulatory approvals to its list during the first quarter and remains one of Merck's most expansive development programs. Current projections suggest *KEYTRUDA* could top $8 billion in sales by 2021. Another drug expected to make increased contributions is *ZEPATIER*. The Hep-C treatment (approved in January, 2016) generated $555 million in sales last year and, based on its strong first-quarter performance ($378 million), is poised to reach blockbuster status in 2017. All told, we continue to view Merck & Co. stock as a solid core holding for investors seeking participation in the large pharmaceutical space. An above-average dividend yield and superior grades for Safety (1) and Financial Strength (A++) should appeal to risk-averse, income-oriented accounts. **About The Company**: Merck & Co. is an international developer, manufacturer, and distributor of pharmaceuticals. Important product names include *JANUVIA/JANUMET* (type-2 diabetes); *ZETIA/VYTORIN* (hypercholesterolemia); *GARDASIL* (vaccine); *KEYTRUDA* (lung cancer); and *REMICADE* (arthritis). In 2014, the company made three significant acquisitions: Schering-Plough (January), Idenix Pharmaceuticals (June), and Cubist Pharmaceuticals (December). *At the time of this article’s writing, the author did not have positions in any of the companies mentioned.* [![Register now for our free One Stock to Buy webinar](https://no-cache.hubspot.com/cta/default/2532383/5a80130b-f0ce-4bd8-acbd-f077f2232ec5.png)](https://cta-redirect.hubspot.com/cta/redirect/2532383/5a80130b-f0ce-4bd8-acbd-f077f2232ec5) ### Popular Posts Search Search Blog ### Topics - [Investing 101 (2)](https://investor.valueline.com/blog/topic/investing-101) - [Market Commentary (37)](https://investor.valueline.com/blog/topic/market-commentary) - [Stock Highlights (390)](https://investor.valueline.com/blog/topic/stock-highlights) - [Stock Market Today (2071)](https://investor.valueline.com/blog/topic/stock-market-today) Copyright 2026 Value Line, Inc. All Rights Reserved. Factual material is obtained from sources believed to be reliable and is provided without warranties of any kind. VALUE LINE IS NOT RESPONSIBLE FOR ANY ERRORS OR OMISSIONS HEREIN OR ANY DAMAGES OR LOSSES ARISING FROM ANY USE OF THE INFORMATION CONTAINED HEREIN. This blog is strictly for subscriber's own, non-commercial, internal use. No part of it may be reproduced, stored or transmitted in any printed, electronic or other form, or used for generating or marketing any printed or electronic publication, service or product. Officers, directors, or employees of Value Line, Inc. and its affiliates and subsidiaries, and EULAV Asset Management, may own stocks that are featured in this email. Nothing herein should be construed as an offer to buy or sell securities or to give individual investment advice. Value Line, the Value Line logo, The Most Trusted Name in Investment Research, “Smart research. Smarter investing.”, The Value Line Investment Survey, Timeliness, and Safety are trademarks or registered trademarks of Value Line, Inc. and/or its affiliates in the United States and other countries.